首页> 美国卫生研究院文献>Lippincott Williams Wilkins Open Access >Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model
【2h】

Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model

机译:与大肠癌模型中的标准大小和摄取指标相比对18F-FDG PET肿瘤异质性的测量改善了对贝伐单抗反应的早期评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeTreatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab. Size measurements are inadequate to assess treatment response to these agents, and newer response assessment criteria are needed. We aimed to evaluate 18F-FDG PET-derived texture parameters in a preclinical colorectal cancer model as alternative metrics of response to treatment with bevacizumab.
机译:目的转移性大肠癌的治疗通常包括抗血管生成药,例如贝伐单抗。尺寸测量不足以评估对这些药物的治疗反应,因此需要更新的反应评估标准。我们旨在评估临床前结直肠癌模型中 18 F-FDG PET衍生的质地参数,作为贝伐单抗治疗反应的替代指标。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号